| Current antioxidant treatments in organ transplantation S Shi, F Xue Oxidative medicine and cellular longevity 2016 (1), 8678510, 2016 | 57 | 2016 |
| Necroptotic cell death in liver transplantation and underlying diseases: mechanisms and clinical perspective S Shi, MMA Verstegen, L Mezzanotte, J de Jonge, CWGM Löwik, ... Liver Transplantation 25 (7), 1091-1104, 2019 | 45 | 2019 |
| Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation F Xue, S Shi, Z Zhang, C Xu, J Zheng, T Qin, Z Qian, X Zhao, Y Tong, ... Oncology letters 15 (4), 5481-5488, 2018 | 36 | 2018 |
| Recapitulating cholangiopathy-associated necroptotic cell death in vitro using human cholangiocyte organoids S Shi, MMA Verstegen, HP Roest, AI Ardisasmita, W Cao, FJM Roos, ... Cellular and Molecular Gastroenterology and Hepatology 13 (2), 541-564, 2022 | 25 | 2022 |
| Mitochondrial dysfunction and oxidative stress in liver transplantation and underlying diseases: new insights and therapeutics S Shi, L Wang, LJW van der Laan, Q Pan, MMA Verstegen Transplantation 105 (11), 2362-2373, 2021 | 25 | 2021 |
| The biological process of lysine‐tRNA charging is therapeutically targetable in liver cancer R Zhang, L Noordam, X Ou, B Ma, Y Li, P Das, S Shi, J Liu, L Wang, P Li, ... Liver International 41 (1), 206-219, 2021 | 17 | 2021 |
| Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids L Wang, M Li, B Yu, S Shi, J Liu, R Zhang, I Ayada, MMA Verstegen, ... Journal of Molecular Medicine 100 (3), 471-484, 2022 | 16 | 2022 |
| Modeling bile duct ischemia and reoxygenation injury in human cholangiocyte organoids for screening of novel cholangio-protective agents S Shi, HP Roest, TPP van den Bosch, MJC Bijvelds, MU Boehnert, ... EBioMedicine 88, 2023 | 11 | 2023 |
| Liver ischemia and reperfusion induce periportal expression of necroptosis executor pMLKL which is associated with early allograft dysfunction after transplantation S Shi, E Bonaccorsi-Riani, I Schurink, T van den Bosch, M Doukas, ... Frontiers in Immunology 13, 890353, 2022 | 11 | 2022 |
| Modeling ischemic cholangiopathy in human cholangiocyte organoid for screening of novel cholangio-protective agents S Shi, H Roest, J de Jonge, J Ijzermans, M Verstegen, L van der Laan Transplantation 106 (suppl 8), 21, 2022 | 1 | 2022 |
| High Mobility Group Box Protein 1 Release Is an Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia S Shi, S Chen, MMA Verstegen, Q Pan, LJW van der Laan Hepatology, 2021 | 1 | 2021 |
| Clinical applications of human organoids MMA Verstegen, RP Coppes, A Beghin, P De Coppi, MFM Gerli, ... Nature Medicine, 1-13, 2025 | | 2025 |
| an den, Bi elds, M S Shi, HP Roest, TPP Bosch C., Boehnert, MU, onge,. de,… Laan, L.. W. an der, 2023 | | 2023 |
| Histological score of necroptosis executor phosphorylated MLKL is associated with increased risk for early allograft dysfunction after liver transplantation S Shi, E Bonaccorsi-Riani, I Schurink, M Doukas, M Verstegen, H Roest, ... TRANSPLANTATION 106 (8 S), 98-98, 2022 | | 2022 |
| Mutations in BAP1 drive tumour sensitivity to programmed cell death in patient-derived cholangiocarcinoma orgnaoids S Shi, IF Schene, IP Joore, HP Roest, G van Tienderen, R Lieshout, ... Journal of Hepatology 77, S652-S653, 2022 | | 2022 |
| General introduction and outline of the thesis S Shi, MMA Verstegen, L Mezzanotte, J de Jonge, CWGM Löwik, ... Programmed cell death in cholangiopathies, liver cancer, and liver …, 2022 | | 2022 |
| High-mobility group box 1 (HMGB1) as a prognostic marker for early allograft dysfunction and ischemic-type biliary lesions in human liver transplantation S Shi, H Roest, R Mammadov, I Schurink, M Verstegen, J Ijzermans, ... TRANSPLANTATION 105 (8), 147-148, 2021 | | 2021 |
| Cholangiopathy-related necroptotic cell death recapitulated in human cholangiocyte organoids for screening novel drug targets S Shi, M Verstegen, J Ijzermans, LJW van der Laan JOURNAL OF HEPATOLOGY 75, S418-S418, 2021 | | 2021 |
| HIGH-MOBILITY GROUP BOX 1 (HMGB1) AS A PROGNOSTIC MARKER FOR EARLY ALLOGRAFT DYSFUNCTION AND ISCHEMIC-TYPE BILIARY LESIONS IN HUMAN LIVER TRANSPLANTATION S Shi, HP Roest, MMA Verstegen, JNM IJzermans, LJW Van Der Laan The Liver Meeting Digital Experience™, 2020 | | 2020 |
| MODELING PROGRAMMED CELL DEATH PATHWAYS IN HUMAN LIVER ORGANOIDS S Shi, MMA Verstegen, JNM IJzermans, LJW Van Der Laan The Liver Meeting Digital Experience™, 2020 | | 2020 |
Luc van der LaanProfessor at Erasmus MC-University Medical center RotterdamEmail verificata su erasmusmc.nl